Why Is AT&T Stock Dropping?
The telecommunications giant AT&T Inc. (NYSE:T) has perhaps surprisingly eclipsed…
Sell
36
RIGL Quote, Financials, Valuation and Earnings
Last price:
$20.23
Seasonality move
:
-6.22%
Day range:
$17.28 - $20.52
52-week range:
$7.48 - $29.82
Dividend yield:
0%
P/E ratio:
87.52x
P/S ratio:
2.24x
P/B ratio:
--
Volume:
582.5K
Avg. volume:
299.3K
1-year change:
49.11%
Market cap:
$354.6M
Revenue:
$116.9M
EPS (TTM):
$0.23
Analysts' Opinion
-
Consensus RatingRigel Pharmaceuticals has received a consensus rating of Hold. The company's average rating is a Hold based on 1 Buy rating, 4 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $30.50, Rigel Pharmaceuticals has an estimated upside of 51.52% from its current price of $20.13.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $14.00 representing 100% downside risk from its current price of $20.13.
Fair Value
-
According to the consensus of 5 analysts, Rigel Pharmaceuticals has 51.52% upside to fair value with a price target of $30.50 per share.
RIGL vs. S&P 500
-
Over the past 5 trading days, Rigel Pharmaceuticals has overperformed the S&P 500 by 20.37% suggesting its relative strength compared to the major market average is strong at this time.
Share Buyback
-
Rigel Pharmaceuticals does not have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Rigel Pharmaceuticals has grown year-over-year revenues for 3 quarters straight. In the most recent quarter Rigel Pharmaceuticals reported revenues of $55.3M.
Earnings Growth
-
Rigel Pharmaceuticals earnings have been falling on a year-over-year basis for 1 quarter in a row. In the most recent quarter Rigel Pharmaceuticals reported earnings per share of $0.70.
Enterprise value:
353.2M
EV / Invested capital:
--
Price / LTM sales:
2.24x
EV / EBIT:
30.06x
EV / Revenue:
2.24x
PEG ratio (5yr expected):
--
EV / Free cash flow:
34.10x
Price / Operating cash flow:
34.09x
Enterprise value / EBITDA:
25.84x
Gross Profit (TTM):
$140.8M
Return On Assets:
3.1%
Net Income Margin (TTM):
2.47%
Return On Equity:
--
Return On Invested Capital:
12%
Operating Margin:
25.42%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2023-09-30 | 2024-09-30 | |
| Income Statement | ||||||
| Revenue | $89.4M | $132.4M | $157.5M | $28.1M | $55.3M | |
| Gross Profit | $87.5M | $128.7M | $140.8M | $26.9M | $47.3M | |
| Operating Income | -$75.5M | -$19.1M | $9.5M | -$4.5M | $14.1M | |
| EBITDA | -$77.7M | -$17.1M | $13.7M | -$3.5M | $15.1M | |
| Diluted EPS | -$4.80 | -$1.41 | $0.23 | -$0.33 | $0.70 | |
| Period Ending | 2020-09-30 | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $99.8M | $171.1M | $110.4M | $95M | $106.5M | |
| Total Assets | $123.1M | $186.5M | $115.6M | $115.3M | $139.4M | |
| Current Liabilities | $34.2M | $59.3M | $47.3M | $48.3M | $54.3M | |
| Total Liabilities | $72.1M | $136.8M | $135.4M | $147.2M | $154.1M | |
| Total Equity | $51M | $49.7M | -$19.8M | -$31.8M | -$14.6M | |
| Total Debt | $19.8M | $19.9M | $39.5M | $59.7M | $59.8M | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2023-09-30 | 2024-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$70.9M | -$21.4M | $10.7M | -$1.4M | $21.7M | |
| Cash From Investing | $60.7M | $21.2M | $8.2M | -$1.2M | $3.8M | |
| Cash From Financing | $9.7M | $15.8M | -$12.6M | -$869K | -$9.8M | |
| Free Cash Flow | -$71.3M | -$36.5M | $10.4M | -$1.4M | $21.7M | |
RIGL
Sector
Market Cap
$354.6M
$45.2M
Price % of 52-Week High
67.51%
46.55%
Dividend Yield
0%
0%
Shareholder Yield
--
-0.75%
1-Year Price Total Return
49.11%
-33.5%
Beta (5-Year)
1.313
0.747
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Technicals
8-day SMA
Buy
Level
$17.36
200-day SMA
Buy
Level
$14.01
Bollinger Bands (100)
Buy
Level
13.16 - 22.16
Chaikin Money Flow
Sell
Level
-191.2M
20-day SMA
Buy
Level
$17.11
Relative Strength Index (RSI14)
Buy
Level
58.75
ADX Line
Buy
Level
23.94
Williams %R
Sell
Level
-7.677
50-day SMA
Sell
Level
$20.83
MACD (12, 26)
Sell
Level
-0.61
25-day Aroon Oscillator
Sell
Level
-36
On Balance Volume
Neutral
Level
372.6M
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (-14.8124)
Sell
CA Score
(Annual)
Level (-3.8204)
Buy
Beneish M-Score
(Annual)
Level (-3.4604)
Buy
Momentum Score
Level (10)
Sell
Ohlson Score
Level (6.9808)
Buy
Piotroski F Score
(Annual)
Level (6)
Buy
Quality Ratio Score
Level (7)
Sell
Fundamental Score
Level (3)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's lead drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, the only oral spleen tyrosine kinase (SYK) inhibitor, Fostamatinib, R289, R552, R835, DS-3032, THF-beta Inhibitors, and AZD0449- Inhaled JAK Inhibitor.
Stock Forecast FAQ
In the current month, RIGL has received 1 Buy ratings 4 Hold ratings, and 0 Sell ratings. The RIGL average analyst price target in the past 3 months is $30.50.
-
Where Will Rigel Pharmaceuticals Stock Be In 1 Year?
According to analysts, the consensus estimate is that Rigel Pharmaceuticals share price will rise to $30.50 per share over the next 12 months.
-
What Do Analysts Say About Rigel Pharmaceuticals?
Analysts are divided on their view about Rigel Pharmaceuticals share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Rigel Pharmaceuticals is a Sell and believe this share price will drop from its current level to $14.00.
-
What Is Rigel Pharmaceuticals's Price Target?
The price target for Rigel Pharmaceuticals over the next 1-year time period is forecast to be $30.50 according to 5 Wall Street analysts, 1 of them rates the stock a Buy, 0 rate the stock a Sell, and 4 analysts rate the stock a Hold.
-
Is RIGL A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Rigel Pharmaceuticals is a Hold. 4 of 5 analysts rate the stock a Hold at this time.
-
How Can I Buy Shares Of RIGL?
You can purchase shares of Rigel Pharmaceuticals via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, TastyTrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Rigel Pharmaceuticals shares.
-
What Is The Rigel Pharmaceuticals Share Price Today?
Rigel Pharmaceuticals was last trading at $20.23 per share. This represents the most recent stock quote for Rigel Pharmaceuticals. Yesterday, Rigel Pharmaceuticals closed at $20.13 per share.
-
How To Buy Rigel Pharmaceuticals Stock Online?
In order to purchase Rigel Pharmaceuticals stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is American Express Stock Going Lower?
American Express Company (NYSE:AXP) has long been a Buffett favorite…
Cigna vs Costco Stock: Which Is Best?
Cigna and Costco don’t usually go hand in hand but…
Stock Ideas
Sell
46
Is AAPL Stock a Buy?
Market Cap: $3.5T
P/E Ratio: 38x
Buy
51
Is NVDA Stock a Buy?
Market Cap: $3.4T
P/E Ratio: 115x
Buy
53
Is MSFT Stock a Buy?
Market Cap: $3.2T
P/E Ratio: 36x
Alerts
Sell
45
QMCO alert for Jan 18
Quantum [QMCO] is down 15.61% over the past day.
Buy
51
QRVO alert for Jan 18
Qorvo [QRVO] is up 14.47% over the past day.
Sell
31
ATEX alert for Jan 18
Anterix [ATEX] is up 11.14% over the past day.
